Objective: Schizoaffective disorder is a complex illness for which optimal treatment is not
well established. Results of the first controlled, relapse-prevention study of paliperidone …

Importance Treatment nonadherence and relapse are common problems in patients with
schizophrenia. The long-acting 3-month formulation of paliperidone palmitate, owing to its …

Background: Limited data are available to help identify patients with schizophrenia who are
most likely to benefit from long-acting injectable antipsychotics. Aim: To investigate the …

Objective: The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE)
study compared the effects of once-monthly paliperidone palmitate with daily oral …

Background: Public health considerations require that clinical trials address the complex"
real-world" needs of patients with chronic illnesses. This is particularly true for persons with …

Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic
formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have …

Background A post hoc analysis from a multiphase trial with open-label transition and
maintenance phases, a double-blind relapse prevention phase, and an optional open-label …

OBJECTIVE: We assessed efficacy and tolerability of the injectable atypical antipsychotic
paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia. METHODS …

Background Persons with schizophrenia often come in contact with the criminal justice
system (CJS). This analysis of subjects with schizophrenia and a history of contact with the …

ObjectiveThis analysis of the Paliperidone Palmitate Research in Demonstrating
Effectiveness (PRIDE) study (NCT01157351) compared outcomes after administration of …